Impartner Launches the First CPQ Built for Partners
20.8.2026 15:00:00 CEST | Business Wire | Press release
New quote management capability brings configure, price, and quote (CPQ) into Impartner’s PRM platform, connecting product configuration, pricing, segmentation, and approvals.
Impartner, the leading partner revenue orchestration platform, today announced the launch ofImpartner CPQ, giving partners a direct path to create and advance quotes within the Impartner PRM platform. The new capability enables faster movement from opportunity to submission while giving vendors control over the rules, products, pricing, and approvals that govern each transaction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820479441/en/
Give partners a faster path from opportunity to quote with Impartner's CPQ.
For many partnership programs, quoting remains a largely manual process. Partners often depend on vendor sales teams to prepare quotes because traditional CPQ systems are designed primarily for direct sellers or require additional licensing for external users. The result is a slower path from opportunity to revenue, increased administrative work for channel teams, and a partner experience that can limit the impact of programs.
Impartner CPQ brings the process directly into the partnership workflow. Users can access a vendor-controlled product catalog and configure offerings based on their tier and segment. They can apply established pricing rules, create and compare versions, and designate a primary proposal. Once ready, the proposal can be submitted for approval within the Impartner platform.
Unlike traditional CPQ solutions built around direct sales organizations, Impartner CPQ is purpose-built for channel partner ecosystems and operates as part of the existing PRM platform. It leverages partner segmentation, tiering, and deal registration to create a connected workflow rather than requiring a separate system for external users.
This approach brings vendor governance and self-service execution together. Vendors can define product catalogs, tier-based pricebooks, pricing rules, and approval requirements, while users can configure products and bundles, manage configurable attributes, create multiple versions, and submit a primary proposal through Impartner’s approval workflow.
The solution supports a range of channel business models, including distributor, VAR, and reseller programs, as well as hyperscaler co-sell motions. It also supports organizations running channel programs on HubSpot or Microsoft Dynamics, operating without a CRM, or using Salesforce without extending CPQ capabilities across large external user populations.
“Quoting should not be the point where a partner opportunity slows down,” said Impartner’s VP of Product Management, Robert Harris. “In a direct sales model, sellers have the tools and authority to move an opportunity from one stage to the next. Vendor companies have historically had to bridge the partner quoting gap through manual processes and internal team intervention. We’re changing that dynamic by giving partners a direct path to act while preserving the controls vendors need to run their business. The result is a partnership motion that can move at the speed of the opportunity, not the speed of the process.”
For vendors, Impartner CPQ helps streamline partner operations while maintaining oversight of catalog access, pricing, and approvals. For partners, it provides a more direct path from opportunity to submission without relying on a vendor representative for every transaction.
Explore Impartner CPQ and discover a more efficient path from opportunity to submission here.
About Impartner
Impartner is the world’s leading partner revenue orchestration platform. Built on a foundation of partner relationship management (PRM), Impartner helps organizations run partner-led growth as a core part of their business, bringing together partner management, partner marketing, deal execution, hyperscaler GTM, automation, and analytics in one platform. Designed for how partner programs operate today, Impartner gives revenue and partner teams the ability to automate go-to-market execution, scale marketplace motions, and see exactly how partners contribute to pipeline and revenue. Learn more at impartner.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260820479441/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom